following a full submission:
certolizumab pegol (Cimzia®) is accepted for restricted use within NHSScotland.
Indication under review: the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Certolizumab pegol has shown a similar reduction in the signs and symptoms of psoriasis in adults with moderate to severe plaque psoriasis compared with another tumour necrosis factor (TNF) antagonist.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of certolizumab pegol. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
- Medicine name:
- certolizumab pegol (Cimzia)
- SMC ID:
- Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Submission type
- Date advice published:
- 08 April 2019